34 completed, 6 unknown, 5 terminated, 4 recruiting. 52 Phase 3, 6 Phase 2.
Follow Fluconazole: new trials by email Literature Review of Fluconazole trials Research Report on Fluconazole
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Optimizing Care for Cryptococcal Antigenemia: Evaluation of Short Course Fluconazole and ART Timing Among CrAg+ Persons With Low Titers Immediate ART Initiation, Delayed ART Initiation, 10-Week Fluconazole - Cryptococcal Antigenemia, HIV-1-infection | Phase 3 | Not yet recruiting | University of Minnesota | 505 | 2027-01-05 | 2026-09-03 |
| Rezafungin Prophylaxis in Liver Transplant Rezafungin, Standard of care antifungal prophylaxis - Liver Transplant Infection, Fungal Infection | Phase 3 | Enrolling by invitation | Fernanda P Silveira, MD, MS | 385 | 2025-10-15 | 2026-09-29 |
| A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis. Fosmanogepix, Caspofungin, Fluconazole - Candidemia, Candidiasis, Invasive | Phase 3 | Recruiting | Basilea Pharmaceutica | 450 | 2024-12-11 | 2026-10-19 |
| Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease Fluconazole, Placebo, IL-23 Therapy - Crohn's Disease, Inflammatory Bowel Diseases | Phase 3 | Recruiting | Weill Medical College of Cornell University | 120 | 2024-10-04 | 2026-08-20 |
| Safety and Efficacy of Intralesional 0.5% Triamcinolone Acetonide in 0.2% Fluconazole Solution vs 0.1% Topical Mometasone Furoate With 2% Miconazole Nitrate Cream in the Treatment of Chronic Paronychia: An Intraindividual Randomized Controlled Trial. Intralesional triamcinolone acetonide and fluconazole, Topical mometasone furoate and miconazole nitrate, Elica-M® - Chronic Paronychia | Phase 3 | Active not recruiting | Cairo University | 21 | 2024-08-17 | 2025-12-31 |
| The Effect of Medical Grade Honey Formulation (L-Mesitran) Administration on Recurrent Vulvovaginal Candidiasis Symptoms Fluconazole, L-Mesitran - Candidiasis, Vulvovaginal, Recurrent Candidiasis of Vagina | Phase 3 | Recruiting | Maastricht University Medical Center | 252 | 2022-08-22 | 2023-05-17 |
| A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole SCY-078, Fluconazole, Echinocandin - Candidiasis, Invasive, Candidemia | Phase 3 | Terminated | Scynexis, Inc. | 68 | 2022-08-03 | 2026-08-10 |
| A Study to Evaluate the Efficacy and Safety of SHR8008 vs. Fluconazole in Subjects With Recurrent Vulvovaginal Candidiasis SHR8008, Fluconazole - Recurrent Vulvovaginal Candidiasis | Phase 3 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 196 | 2021-09-14 | 2021-10-12 |
| Efficacy of Prophylactic Fluconazole Therapy in Preterm and Very Low Birth Weight Neonates in Preventing Invasive Fungal Infection. Fluconazole, Saline - Invasive Candidiases | Phase 3 | Completed | Services Institute of Medical Sciences, Pakistan | 110 | 2021-05-01 | 2023-05-08 |
| A Study to Evaluate the Efficacy and Safety of SHR8008 vs. Fluconazole in Subjects With Acute Vulvovaginal Candidiasis SHR8008 capsule, Fluconazole capsule - Acute Vulvovaginal Candidiasis | Phase 3 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 322 | 2021-04-24 | 2021-09-16 |
| Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation Rezafungin for Injection, Posaconazole, Fluconazole - Candidemia, Mycoses | Phase 3 | Completed | Mundipharma Research Limited | 602 | 2020-05-11 | 2026-04-13 |
| Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC) Fluconazole Tablet, IBREXAFUNGERP, Placebo oral tablet - Recurrent Vulvovaginal Candidiasis | Phase 3 | Completed | Scynexis, Inc. | 440 | 2019-10-21 | 2023-06-18 |
| A Phase IIb/III Study of Prof-001 for the Treatment of Patients With Recurrent Vulvovaginal Candidiasis (RVVC) Prof-001, Fluconazole 150 mg, Placebo cream - Recurrent Vulvovaginal Candidiasis | Phase 2 / Phase 3 | Unknown | ProFem GmbH | 432 | 2019-10-01 | 2022-09-22 |
| Single Dose Liposomal Amphotericin for Asymptomatic Cryptococcal Antigenemia Single dose liposomal Amphotericin and Fluconazole, Fluconazole - Cryptococcal Meningitis | Phase 2 / Phase 3 | Recruiting | Makerere University | 356 | 2019-06-20 | 2026-04-28 |
| Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast Infections Oteseconazole (VT-1161) 150mg capsule, Fluconazole 150mg capsule, Placebo - Recurrent Vulvovaginal Candidiasis | Phase 3 | Completed | Mycovia Pharmaceuticals Inc. | 219 | 2019-03-13 | 2022-02-04 |
| Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis Rezafungin for Injection, Caspofungin, Fluconazole - Candidemia, Mycoses | Phase 3 | Completed | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 199 | 2018-10-07 | 2023-01-06 |
| Cryptococcal Antigen Screening Plus Sertraline Sertraline, Placebo Oral Tablet, Fluconazole - Cryptococcosis, Cryptococcal Infections | Phase 3 | Terminated | University of Minnesota | 22 | 2017-11-15 | 2020-06-09 |
| Antifungal Drugs in Treatment of Onychomycosis Terbinafine - Antifungal Drugs in Onychomycosis | Phase 3 | Unknown | Assiut University | 60 | 2017-07-01 | 2017-05-31 |
| Fluconazole Versus Micafungin in Neonates With Candidiasis Fluconazole, Micafungin - Candidiasis | Phase 2 / Phase 3 | Completed | Institut National de la Santé Et de la Recherche Médicale, France | 100 | 2014-10-01 | 2025-09-04 |
| High Dose Fluconazole in Cutaneous Leishmaniasis in Bahia and Manaus Fluconazole, Meglumine Antimoniate - Cutaneous Leishmaniasis | Phase 3 | Terminated | Hospital Universitário Professor Edgard Santos | 53 | 2014-02-01 | 2015-12-02 |
Showing 20 of 52. Sign in to see all of them.
Mycoses (11) · Candidemia (9) · Candidiasis (9) · Candidiasis, Invasive (9) · Candidiasis, Vulvovaginal (7) · HIV Infections (7) · Acquired Immunodeficiency Syndrome (5) · Infections (4) · Invasive Fungal Infections (4) · Meningitis, Cryptococcal (4) · AIDS-Related Opportunistic Infections (3) · Fungemia (3) · Torulopsis (3) · Candidiasis, Oral (2) · Cryptococcosis (2)
Pfizer (10) · Astellas Pharma Inc (3) · Children's Oncology Group (2) · Jiangsu HengRui Medicine Co., Ltd. (2) · Merck Sharp & Dohme LLC (2) · Scynexis, Inc. (2) · University of Minnesota (2) · ANRS, Emerging Infectious Diseases (1) · Anna Griffiths, MRC (1) · Asan Medical Center (1) · Assiut University (1) · Basilea Pharmaceutica (1) · Cairo University (1) · Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) · Daniel Benjamin (1)
United States (25) · Italy (8) · Belgium (7) · France (7) · Spain (7) · Canada (6) · China (6) · Germany (6) · Greece (5) · South Korea (5) · Austria (4) · Brazil (4) · Taiwan (4) · Uganda (4) · United Kingdom (4)
Radha Rajasingham, MD (2) · Alexandra Hill, MD (1) · Andrea E Rodriguez, MD, MsC (1) · Ariel I Ruiz, MD, MsC (1) · Armstrong D (1) · Arnold M. Markoe, MD, ScD (1) · Bozzettee S (1) · Christopher C Dvorak (1) · Daniel K Benjamin, MD MPH PhD (1) · David Angulo, MD (1) · David N Herndon, MD (1) · Diana M Gibb (1) · Dismukes W (1)
PMID 33438477, PMID 14964746, PMID 17568028, PMID 19734776, PMID 19915602, PMID 19968146, PMID 20826719, PMID 20881067, PMID 22463890, PMID 22565425, PMID 22606232, PMID 22895351, PMID 23150682, PMID 23303450, PMID 23924680, PMID 23943184, PMID 23959319, PMID 24009246, PMID 24079585, PMID 24298851, PMID 24352873, PMID 24655871, PMID 24794367, PMID 24824900, PMID 24918945, PMID 25211297, PMID 25514427, PMID 25520332, PMID 25807408, PMID 25887336, PMID 27171844, PMID 27433905, PMID 27803094, PMID 28240622, PMID 28459966, PMID 28597967, PMID 29653915, PMID 29744900, PMID 30418357, PMID 30513108, PMID 31066013, PMID 31280481, PMID 31688884, PMID 32032174, PMID 32103268, PMID 32415846, PMID 33136159, PMID 33891293, PMID 34432828, PMID 36396498
2008 (2), U10CA095861 (2), UG1CA189955 (2), 2017 (1), P50GM060338 (1), R01HD057956 (1), U01AI125003 (1), U01HL069294 (1), U24CA076518 (1)